AI-driven drug discovery

Adipothera is a drug discovery company developing AI-driven therapies targeting the stromal microenvironment for diseases driven by fibrosis and inflammation. Its pipeline generates first-in-class drug candidates that are computationally guided, assay-proven, and clinically motivated. Lead candidates include AT-001 (topical) for radiation injury and lymphedema, and AT-002 (oral) for Fibrodysplasia Ossificans Progressiva (FOP) and Heterotopic Ossification (HO).

computational drug designin-silico triagePK/PD modelingpreclinical assaystopical and oral drug formulation

BioDawn Innovations is a research company focused on revolutionizing drug discovery using artificial intelligence, with a primary focus on aging-related illnesses and cancer. Founded by a group of seasoned researchers specialized in cancer and aging, the company develops AI to accelerate discovery of new therapeutics, builds an AI-powered platform for precision medicine tailored to each patient's needs, and uses AI algorithms to optimize efficacy and safety profiles of existing drugs.

biomedical researchdrug optimizationprecision medicine

Bound Therapeutics is a preclinical-stage biotechnology company developing RNA-based therapies for rare and refractory diseases, with a primary focus on oncology. Its proprietary Magic Bullet Designer (MBD) platform uses AI and machine learning to design tissue-targeted peptide ligands for RNA drug delivery. The company was founded in 2015 and is located at the Cambridge Innovation Center in Philadelphia, PA.

de novo peptide ligand designmachine learningnanoparticle engineeringpreclinical researchRNA therapeutics developmenttissue-targeted drug delivery

CardiaTec Biosciences Ltd is a TechBio company registered in England and Wales that leverages large-scale multiomics data to discover novel cardiovascular therapeutics. The company decodes heart tissue multiomics data for cardiovascular therapy development and has raised seed funding led by Montage Ventures.

cardiovascular therapy developmentmultiomics data analysis

Double Bond Pharmaceutical is a pharmaceutical company founded in 2014 by Dr. Igor Lokot that develops and commercializes innovative first-in-class treatments for cancers and infectious diseases. It focuses on redeveloping known drugs by changing the route of administration to create new formulations that reduce side effects and improve efficacy, with expertise in brain cancer, liver cancer and pneumonia.

clinical researchdrug delivery systemsdrug developmentreformulation of known drugs

Fauna Bio is an AI-driven drug discovery company leveraging data from 100 million years of evolved disease resistance in mammals. Using its exclusive biobank of genetic data and its in-house Convergence™ platform, it replicates how extreme animal models resist disease to create new drugs for humans. It has a multi-year $494M agreement with Eli Lilly for preclinical drug discovery in obesity, and runs space-focused research programs on hibernation and radiation protection.

computational biologyConvergence™ AI platformgenetic data biobankin-vivo experimentspreclinical drug discoverytarget identification